Competent, Connected, Entrepreneurial, Experienced
Rare Disease
& Biopharma
Consulting
Coworking
Coaching
Consulting
Coworking
Coaching
Welcome!
Are you looking for a partner to significantly accelerate the commercial success of your rare disease therapies in an increasingly complex, cost-limited, regulated and competitive environment?
Founded in 2018, Trisalta is focusing on 3 core areas in the rare disease biopharmaceutical environment: Consulting: we are your consultant to enable entrepreneurial orphan drug business and access solutions, building on decades of industry expertise of Trisalta’s management and subject-matter expert network. Coworking: your interim management for short- and medium-term bottlenecks, vacancies at local executive and senior operational management level. Coaching: based on our long-lasting experience, we support your local business leader in the journey of developing essential core skills and competencies to implement and execute your ambitious local orphan drug business plan successfully.
Our promise
Getting your innovative orphan drug therapy into the hands of qualified healthcare professionals as quickly as possible to make a difference for patients‘ lives and to enhance your commercial success.
Building on more than 30 years’ experience in the German, DACH & European biopharmaceutical market of orphan drugs and rare diseases.
Providing a strong local network of selected, highly experienced specialists for all key steps and of the commercialization and market access roadmap.
We are your trusted and committed partner for the successful market preparation and commercialization of your innovative rare disease therapy, addressing the unmet medical need of small patient populations.
Key focus areas
Getting your innovative orphan drug therapy into the hands of qualified healthcare professionals as quickly as possible to make a difference for patients‘ lives and to enhance your commercial success.
Building on more than 30 years’ experience in the German, DACH & European biopharmaceutical market of orphan drugs and rare diseases.
Providing a strong local network of selected, highly experienced specialists for all key steps and of the commercialization and market access roadmap.
We are your trusted and committed partner for the successful market preparation and commercialization of your innovative rare disease therapy, addressing the unmet medical need of small patient populations.
Core capabilities
Commercial leadership over all phases of the German AMNOG reimbursement & pricing process
Local launch planning
Local organizational implementation: roadmap/ co-working/ interim management/ guidance
Founded 2018
GM and founder: Hans Peter Halbritter
Member of European expert network Orphan Now Consulting
Key areas of expertise (DACH):
- Commercial planning
- Launch planning
- Landscape mapping: expert centers, KOLs, key stakeholders, patient advocacy groups
- Commercial AMNOG process and price negotiation leadership
- Local epidemiologic (EPI) data assessment
- Market potential assessment
- SWOT and PEST analysis
Most recent therapy areas: rare bone disease, rare liver disease, rare kidney disease, rare immunology in transplantation, rare coagulation disorders & hemophilia, rare dermatology, rare neurological disease, plasma-derived therapies.
Since 2018 Trisalta successfully collaborated with 15 different project clients from 6 different countries incl. US-based pharma, EU-based pharma (France/ Germany), Japan-based pharma, US and EU based rare-disease biotech start ups
Let’s connect!
Trisalta GmbH
Luitpoldring 40b
85591 Vaterstetten
Germany
Phone: +49 (0) 171/8164417
E-Mail: info@trisalta.com
*mandatory field